Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip Tetra) in South Korea
ConclusionThis post-marketing surveillance study confirms that QIV is well tolerated and has an acceptable safety profile in routine practice in South Korea. No unexpected safety concerns were identified.Trial RegistrationClinicalTrials.gov identifier NCT05406180.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research
More News: Common Cold | Infectious Diseases | Influenza | Influenza Vaccine | Legislation | Pain | South Korea Health | Study | Vaccines